EL7.AI
StocksMediumUpdated×2•Originally published 7 March 2026•Updated 8 March 2026•
1 min read

Hims & Hers Shares Skyrocket 40% on Surprise Novo Nordisk Settlement for Wegovy Distribution

Key Facts

1Novo Nordisk plans to sell its weight-loss drug Wegovy on the Hims & Hers Health platform.
2The agreement ends a legal dispute between the two companies that escalated into a legal battle last month.

Hims & Hers Health shares skyrocketed 40% late Friday following the announcement of a legal settlement and strategic partnership with Novo Nordisk. The agreement allows Novo Nordisk to distribute its popular weight-loss medication, Wegovy, through the Hims & Hers digital platform. This surprise move effectively ends a legal battle that had previously weighed on both companies' stock performance, removing a significant layer of uncertainty for investors. The partnership provides Novo Nordisk with a massive new distribution channel to meet the surging global demand for GLP-1 treatments. Market analysts view the shift from litigation to revenue-generating collaboration as a major validation of the Hims & Hers telehealth model. The deal is expected to significantly impact the financial outlook of both entities within the rapidly expanding obesity drug market.